The effects of the atypical antipsychotic amperozide on vacuous jaw movements in rats: A novel dose response profile

Psychopharmacology

Volumn 138, Issue 2, 1998, Pages 107-113

  Steinpreis, Rhea E ^a   Moser, Lorna ^a   Parret, Fola ^a   Rutell, Ethan ^a   Panos, John ^a  

^a UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

Amperozide; Clozapine; Extrapyramidal; Haloperidol; Vacuous jaw movements

Indexed keywords

AMPEROZIDE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; EXTRAPYRAMIDAL SYMPTOM; INJECTION; JAW MOVEMENT; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; SCHIZOPHRENIA; STEREOTYPY;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRAPYRAMIDAL TRACTS; HALOPERIDOL; JAW; MALE; MOVEMENT DISORDERS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031871387     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050652     Document Type: Article

References (69)

1. 2 receptors: an autoradiographic analysis of rat brain. Brain Res Bull 16:517 525
2. Anden NE, Stock G (1973) Effect of clozapine on the turn over of dopamine in the corpus striatum and in the limbic system. J Pharm Pharmacol 25:346 348
3. Anden NE, Butcher SG, Corrodi H, Fuxe K, Ungerstedt U (1970) Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol 11:303 314
4. Angus JWS, Simpson GM (1970) Hysteria and drug induced dystonia. Acta Psychiatr Scand 212:52-58
5. Axelsson R, Nilsson A, Christensson E, Bjork A (1991) Effects of amperozide in schizophrenia. Psychopharmacology 4: 287-292
6. Bartholini G (1976a) Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system. J Pharm Pharmacol 28:429-433
7. Bartholini G (1976b) Preferential effect of noncataleptogenic neuroleptics on the mesocortical dopaminergic function. Adv Biochem Pharmacol 16:607-611
8. Biner RL, Levy R (1981) Extrapyramidal reactions in Asians. Am J Psychiatry 138:1243-1244
9. Burki HR, Ruch W, Asper H, Baggiolini, Stille G (1974) Effect of single and repeated administration of clozapine on the metabolism of dopamine and noradrenaline in the brain of the rat. Eur J Pharmacol 27:180 190
10. Burki HR, Eichenberger E, Sayers AC, White TG (1975a) Clozapine and the dopamine hypotheses of schizophrenia, a critical appraisal. Pharmacopsychiatry 8:115 121
11. Burki HR, Ruch W, Asper H (1975b) The effect of clozapine, thioridazine, perlapine and haloperidol on the metabolism of the biogenic amines in the brae of the rat. Psychopharmacology 41:27-33
12. Burnett GB, Prange AJ, Wilson IC, Jolliff LA, Creese IC, Snyder SH (1980) Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. Neurpsychobiology 6:109-120
13. Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 41:S47-S53
14. Christensson E, Bjork A (1990) Amperozide: A new pharmacological approach in the treatment of schizophrenia. Pharmacol Toxicol 1:5-7
15. Christensson E, Bjork A, Gustafsson B, Nerme V (1981) Pharmacological properties of a new anti-aggressive-compound. Int Cong Pharm Abstr 8:533
16. Claas F (1989) Drug-induced agrantilocytosis: review of possible mechanisms, and prospects for clozapine studies. Psychopharmacology 99:113 117
17. Clow AT, Jenner P, Marsden CD (1979) An experimental model of tardive dyskinesia. Life Sci 23:421-424
18. Costall B, Naylor RJ (1975) Detection of neuroleptic properties of clozapine, sulpiride and thioridazine. Psychopharmacologia 43:69-74
19. Den Boer JA, Verhoeven WMA, Westenberg HGM (1988) Atypical neuroleptics in the treatment of schizophrenia psychoses. New Tre of Exp Clin Psychiatr 4:121 156
20. Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian G K, Bunney BS, Charney DS (1991) Mechanisms of action of atypical antipsychotic drugs: implication for novel therapeutic strategies for schizophrenia. Schizophr Res 4:121 156
21. Egan MF, Ferguson J, Hyde TM (1995) Effects of rating parameters on assesment of neuroleptic-induced vacuous jaw movements. Pharmacol Biochem Behav 53:401-410
22. Egbe PC (1989) Locomotor effects of amperozide. Arzneimittelforschung 39:1223-1224
23. El-Defrawi MH, Craig TJ (1984) Neuroleptics, extrapyramidal symptoms, and serum calcium levels. Comp Psychiatr 26: 539-545
24. Ellingwood EH, Kilbey MM (1977) Advanced behavioral biology, vol 21. Plenum Press, New York
25. Falloon I, Watt DC, Shepherd M (1978) The social outcome of patients in a trial of long-term continuation therapy of schizophrenia: pimozide vs. fluphenazine. Psychiatr Med 8: 265-274
26. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49:538-588
27. Fischer-Cornelssen KA, Ferner UJ (1976) An example of European multicenter trials: multispectral analysis of clozapine. Psychol Bull 12:34 39
28. Gellenberg AJ, Doller JC (1979) Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study. J Clin Psychiatry 40:238-240
29. 2 antagonism in extrapyramidal functions. Br J Psychiatry 160:34-37
30. Glassman RB, Glassman HN (1980) Oral dyskinesia in brain damaged rats withdrawn from a neuroleptic: implication for models of tardive dyskinesia. Psychopharmacology 69:19-25
31. Goldstein MJ, Rodnick EH, Evans JR (1978) Drug and family therapy in the after care treatment of active schizophrenia. Arch Gen Psychiatry 35:1169-1177
32. Grenhoff J, Che-Se Tung, Uqedo L, Svensson TH (1990) Effects of amperozide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo. Pharmacol Toxicol 66:29-33
33. Gunne LM, Andersson U, Bondesson U, Johansson P (1986) Spontaneous chewing movements in rats during acute and chronicantipsychotic drug administration. Pharmacol Biochem Behav 25:897-901
34. Gustafsson B, Christensson E (1990) Amperozide - a new putatively antipsychotic drug with a limbic mode of action on dopamine mediated behavior. Pharmacol Toxicol 66 [Suppl 1]: 12-17
35. Ichikawa J, Meltzer HY (1992a) The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo. Brain Res 574:98-104
36. Ichikawa J, Meltzer HY (1992b) Amperozide, a novel antipsychotic drug, inhibits the ability of d-amphetamine to increase dopamine release in vivo in rat striatum and nucleus accumbens. J Neurosci 58:2285-2291
37. Iversen SD, Howells RB, Hughs RP (1980) Behavioral consequences of long-term treatment with neuroleptic drugs. Adv Biochem Psychopharmacol 24:305-313
38. Jicha F, Salamone JD (1991) Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletions: possible relation to parkinsonian symptoms. J Neurosci 11:3822-3829
39. Johansson P, Casey DE, Gunne LM (1986) Spontaneous chewing movements in rats during long-term administration of haloperidol but not clozapine. Psychopharmacol Bull 22:1017-1019
40. Julou L, Scatton B, Glowinski J (1976) Acute and chronic treatment with neuroleptics: similarities and differences in their action on nigrostriatal, mesolimbic and mesocortical dopaminergic neurons. Adv Biochem Pharmacol 16:617-624
41. Kane J, Honigfield F, Singer J, Meltzer HY, et al. (1988) Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
42. Kimura K, Nomikos GG, Svensson TH (1993) Effects of amperozide on psycho-stimulant-induced hyperlocomotion and dopamine release in the nucleus accumbens. Pharmacol Biochem Behav 44:27-36
43. 2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol 236:483-486
44. Liebermann J, Kane J, Johns C, Vital-Herne J (1986) Clozapine: clinical evidence of novel effects. Clin Neuropharmacol 9:140-141
45. Mertens C, DeWilde J, Dierick M, Bergman L, Gustavssen G (1989) Clinical trials of amperozide in schizophrenia. VIIth World Congress of Psychiatry. Experta Medicale International Congress Series. 899: Amsterdam, p 502
46. Nair NPV, Zichermann V, Schwarz G (1977) Dopamine and schizophrenia. A reappraisal in light of clinical studies with clozapine. Can Psychiatr Assoc J 22:285-293
47. 2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology 90:287-294
48. Ohman R, Axelsson R (1980) Prolactin response to neuroleptics. Clinical and theoretical implications. Relation between serum concentration of thioridazine and its major metabolites and the prolactin response in psychotic patients. J Neurol Transm 17:5-16
49. Pettersson G, Johanssen K, Hulthe P, Engel JA (1990) Effect of amperozide on the synthesis and turnover of monoamines in rat brain. Pharmacol Toxicol 66:40-44
50. Richelson E (1984) Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 45:331-336
51. 1 stimulation. Life Sci 33:2479-2482
52. Roy A (1986) Depression, attempted suicide, and suicide in patients with chronic schizophrenia. Psychiat Clin N Amer 9:193-207
53. Rupniak NMJ, Jenner P, Marsden CD (1983) Cholinergic modulation of perioral behavior induced by chronic neuroleptic administration to rats. Psychopharmacology 79:226-230
54. Rupniak NMJ, Jenner P, Marsden CD (1985) Pharmacological characterization of spontaneous or drug-induced purposeless chewing movements in rats. Psychopharmacology 85:71-79
55. Rupniak NMJ, Jenner P, Marsden CD (1986) Acute dystonia induced by neuroleptic drugs. Psychopharmacology 8:403-419
56. Scheel-Kruger J, Graestrup C, Nielson M, Golembiowski K. Mogilmicka E (1977) Cocaine: discussion on the role of dopamine in the biochemical mechanism of action. In: Ellinwood EH, Kilbey MM (eds) Advances in biology. Vol 21: cocaine and other stimulants. Plenum Press, New York, pp 373-407
57. Schmutz J, Eichenberger E (1982) Clozapine. Chron Drug Dis 1:39-59
58. See RE, Chapman MA, Meshul CK (1992) Comparison of chronic intermittent haloperidol and raclopride effects on striatum dopamine release and synaptic ultrastructure in rats. Synapse 12:147-154
59. 4. Neuropsychopharmacology 7:261-284
60. Steinpreis RE, Salamone JD (1993) Effects of acute haloperidol and reserpine administration on vacuous jaw movements in three different age groups of rats. Pharmacol Biochem Behav 45:323-327
61. Steinpreis RE, Baskin P, Salamone JD (1993) Vacuous jaw movements induced by sub-chronic administration of haloperidol: interactions with scopolamine. Psychopharmacology 111:99-105
62. Steinpreis RE, Sokowlowski JD, Papanikolaou A, Salamone JD (1994) The effects if haloperidol and clozapine on PCP- and amphetamine induced suppression of social behavior in the rat. Pharmacol Biochem Behav 47:579-585
63. Stille G, Lavener H, Eichenberger E (1971) The pharmacology of 8-chloro-11-(4'-methyl-1-piperazinyl)-5II-debenzo[b,e][1,4] diazepine (clozapine). Farm Ed Pract 26:603-625
64. 2 receptors as assessed by in vitro and in vivo binding. Eur J Pharmacol 254:73-81
65. Swerdlow NR, Vaccarino FJ, Amalric M, Koob GF (1986) The neural substrates for the motor-activating properties of psychostimulants: A review of recent findings. Pharmacol Biochem Behav 25:233-248
66. Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31:67-72
67. Volpicelli SA, Centorrino F, Puopolo PR, Kando J, Frankenburg FR, Baldessarini RJ, Flood JG (1993) Determination of clozapine, norclozapine, and clozapine-N-oxide in serum by liquid chromatography. Clin Chem 39:1656 1659
68. Waters N, Pettersson G, Carlsson A, Svensson K (1989) The putatively antipsychotic agent amperozide produces behavioral stimulation in the rat. Naunyn-Schmiedeberg's Arch Pharmacol 340:161-169
69. Yamamoto BK, Cooperman MA (1994) Differential effects if chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 14:4159-4166